| ATC code L: Antineoplastic and immunomodulating agents |
|---|
| Other ATC codes |
ATC code L Antineoplastic and immunomodulating agents is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QL.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
- "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- "ATC/DDD Index 2022: code L". WHO Collaborating Centre for Drug Statistics Methodology.
- "ATCvet Index 2022: code QL". WHO Collaborating Centre for Drug Statistics Methodology.
| Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
|---|---|
| gastrointestinal tract / metabolism (A) | |
| blood and blood forming organs (B) | |
| cardiovascular system (C) | |
| skin (D) | |
| genitourinary system (G) | |
| endocrine system (H) | |
| infections and infestations (J, P, QI) | |
| malignant disease (L01–L02) | |
| immune disease (L03–L04) | |
| muscles, bones, and joints (M) | |
| brain and nervous system (N) |
|
| respiratory system (R) | |
| sensory organs (S) | |
| other ATC (V) | |
| Targeted cancer therapy / antineoplastic agents (L01) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| CI monoclonal antibodies ("-mab") |
| ||||||||
| Tyrosine kinase inhibitors ("-nib") |
| ||||||||
| Other |
| ||||||||
| Immunostimulants (L03) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endogenous |
| ||||||||||||
| Exogenous | |||||||||||||
| Immunosuppressive drugs / Immunosuppressants (L04) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intracellular (initiation) |
| ||||||||||||||
| Intracellular (reception) |
| ||||||||||||||
| Extracellular |
| ||||||||||||||
| Unsorted |
| ||||||||||||||
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |